Advertisement

International Journal of Hematology

, Volume 86, Issue 1, pp 37–41 | Cite as

Prevalence and Incidence of Anemia in Japanese Cancer Patients Receiving Outpatient Chemotherapy

  • Toshiyuki Kitano
  • Harue Tada
  • Tsutomu Nishimura
  • Satoshi Teramukai
  • Masashi Kanai
  • Takafumi Nishimura
  • Akiko Misawa
  • Kiyotsugu Yoshikawa
  • Hiroyasu Yasuda
  • Hiroshi Ishiguro
  • Shigemi Matsumoto
  • Kazuhiro Yanagihara
  • Masanori Fukushima
Progress in Hematology

Abstract

Anemia in cancer patients has been under-recognized and little studied in Japan. To gain some insight into cancer-related anemia in Japanese patients undergoing outpatient chemotherapy, we performed a single-center retrospective study of the prevalence and incidence of anemia in 148 patients with solid tumors treated at the Kyoto University Hospital Outpatient Oncology Unit. We classified the cases of anemia in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Of 148 patients, 65 (44%) were anemic at the start of chemotherapy, 19 (13%) of whom had anemia of grade 2 or higher. Chemotherapy further increased the number of anemic patients, with 125 (84%) being anemic at some point during chemotherapy, and 61 (41 % ) of these having anemia of grade 2 or higher. Among the 83 patients without anemia at the start of chemotherapy, 60 (72%) developed anemia during chemotherapy, 15 (18%) of whom had anemia of grade 2 or higher. This is the first report showing a high prevalence and incidence of anemia in Japanese patients undergoing outpatient chemotherapy. Better recognition and management of cancer-related anemia are required in Japan. To this end, randomized controlled trials evaluating the effects of erythropoietic agents on patients’ survival and quality of life are necessary.

Key words

Cancer-related anemia Outpatient chemotherapy Erythropoietic agents 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment.J Natl Cancer Inst. 1999;91:1616–1634.CrossRefGoogle Scholar
  2. 2.
    Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.Eur J Cancer. 2004;40:2293–2306.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature.Am J Med. 2004;116(suppl 7A):11S-26S.CrossRefGoogle Scholar
  4. 4.
    Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin—an updated overview.Nat Clin Pract Oncol. 2006;3:152–164.CrossRefGoogle Scholar
  5. 5.
    Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer.Cochrane Databas e Syst Rev. 2006;3:CD003407.Google Scholar
  6. 6.
    Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.Cancer. 2002;95:888–895.CrossRefGoogle Scholar
  7. 7.
    Morishima Y, Ogura M, Yoneda S, et al. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.Jpn J Clin Oncol. 2006;36:655–661.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Okamoto H, Saijo N, Shinkai T, et al. Chemotherapy-induced anemia in patients with primary lung cancer.Ann Oncol. 1992;3:819–824.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yoshimura A, Kobayashi K, Fumimoto H, Fujiki Y, Eremenco S, Kudoh S. Cross-cultural validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An).J Nippon Med Sch. 2004;71:314–322.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shouji D, Watanabe C, Mizunuma N, et al. Chemotherapy-induced anemia in solid tumor patients.Ketsueki-Shuyoka. 2006;52:226–236 (in Japanese).Google Scholar
  11. 11.
    Kurita M, Shimozuma K, Morita S, et al. Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy- Anemia Scale.Support Care Cancer. 2007;15:1–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Longo DL, Duffey PL, De Vita VT Jr, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods.J Clin Oncol. 1991;9:2042–2051.CrossRefPubMedGoogle Scholar
  13. 13.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Amer Statistic Assoc. 1958;53:457–481.CrossRefGoogle Scholar
  14. 14.
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.Blood. 2002;100:2303–2320.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:2006 update.Eur J Cancer. 2007;43:258–270.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly.Lancet Oncol. 2003;4:459–460.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.Lancet. 2003;362:1255–1260.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.J Clin Oncol. 2005;23:5960–5972.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?J Clin Oncol. 2006;24:4708–4713.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.J Natl Cancer Inst. 2005;97:489–498.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Toshiyuki Kitano
    • 1
    • 2
  • Harue Tada
    • 3
  • Tsutomu Nishimura
    • 3
  • Satoshi Teramukai
    • 3
  • Masashi Kanai
    • 2
  • Takafumi Nishimura
    • 2
  • Akiko Misawa
    • 2
    • 4
  • Kiyotsugu Yoshikawa
    • 2
  • Hiroyasu Yasuda
    • 2
  • Hiroshi Ishiguro
    • 1
    • 2
  • Shigemi Matsumoto
    • 1
    • 2
  • Kazuhiro Yanagihara
    • 1
    • 2
  • Masanori Fukushima
    • 2
    • 3
  1. 1.Department of Translational Clinical Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Outpatient Oncology UnitKyoto University HospitalKyotoJapan
  3. 3.Department of Clinical Trial Design and ManagementKyoto University HospitalKyotoJapan
  4. 4.Horizontal Medical Research OrganizationKyoto University Faculty of MedicineKyotoJapan

Personalised recommendations